Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 1:35 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 91 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Liver Resection Clear all
Not listed Phase 1 Interventional

A Study to Assess PV-10 Chemoablation of Cancer of the Liver

NCT00986661
View directory record Official record
Conditions
Cancer Metastatic to the Liver, Hepatocellular Carcinoma, Metastatic Melanoma, Metastatic Ocular Melanoma, Metastatic Uveal Melanoma, Metastatic Lung Cancer, Metastatic Colon Cancer, Metastatic Colorectal Cancer, Metastatic Breast Cancer, Metastatic Pancreatic Cancer
Interventions
PV-10 (10% rose bengal disodium)
Drug
Lead sponsor
Provectus Biopharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2023
U.S. locations
5
States / cities
San Diego, California • Tampa, Florida • Bethlehem, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2022 · Synced Oct 22, 2026, 1:35 AM EDT
Completed Phase 1 Interventional

Monoclonal Antibody Therapy in Treating Patients With Colorectal Cancer

NCT00005616
View directory record Official record
Conditions
Colorectal Cancer, Metastatic Cancer
Interventions
conventional surgery, neoadjuvant therapy, radionuclide imaging, iodine I 131 monoclonal antibody F19
Procedure · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2000
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 19, 2013 · Synced Oct 22, 2026, 1:35 AM EDT
Terminated Phase 2 Interventional Results available

Liver Surgery and Chemotherapy in Treating Patients With Colorectal Cancer With Liver Metastases That Can Be Removed by Surgery and Lung Metastases That Cannot Be Removed by Surgery

NCT02738606
View directory record Official record
Conditions
Metastatic Colorectal Carcinoma, Metastatic Malignant Neoplasm in the Liver, Metastatic Malignant Neoplasm in the Lung, Recurrent Colorectal Carcinoma, Resectable Colorectal Carcinoma, Stage IV Colorectal Cancer AJCC v7, Stage IVA Colorectal Cancer AJCC v7, Stage IVB Colorectal Cancer AJCC v7
Interventions
Chemotherapy, Laboratory Biomarker Analysis, Metastasectomy, Quality-of-Life Assessment, Therapeutic Conventional Surgery
Drug · Other · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Oct 22, 2026, 1:35 AM EDT
Completed Phase 1 Interventional

Flt3L in Treating Patients With Metastatic Colorectal Cancer

NCT00003431
View directory record Official record
Conditions
Colorectal Cancer, Metastatic Cancer
Interventions
recombinant flt3 ligand
Biological
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2001
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 5, 2013 · Synced Oct 22, 2026, 1:35 AM EDT
Completed Phase 3 Interventional Results available

Sorafenib as Adjuvant Treatment in the Prevention Of Recurrence of Hepatocellular Carcinoma (STORM)

NCT00692770
View directory record Official record
Conditions
Carcinoma, Hepatocellular
Interventions
Nexavar (Sorafenib, BAY43-9006), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
1,114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
29
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 20 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2018 · Synced Oct 22, 2026, 1:35 AM EDT
Terminated Phase 3 Interventional Results available

Oxaliplatin and Capecitabine With or Without an Hepatic Arterial Infusion With Floxuridine in Treating Patients Who Are Undergoing Surgery and/or Ablation for Liver Metastases Due to Colorectal Cancer

NCT00268463
View directory record Official record
Conditions
Colorectal Cancer, Metastatic Cancer
Interventions
capecitabine, floxuridine, oxaliplatin
Drug
Lead sponsor
NSABP Foundation Inc
Network
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
31
States / cities
Concord, California • Duarte, California • Loma Linda, California + 23 more
Source: ClinicalTrials.gov public record
Updated May 15, 2013 · Synced Oct 22, 2026, 1:35 AM EDT
Terminated Phase 2 Interventional Results available

Combination Chemotherapy and Bevacizumab Before Surgery and Radiolabeled Monoclonal Antibody Therapy in Treating Liver Metastases in Patients With Metastatic Colorectal Cancer

NCT01320683
View directory record Official record
Conditions
Liver Metastases, Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IVA Colon Cancer, Stage IVA Rectal Cancer, Stage IVB Colon Cancer, Stage IVB Rectal Cancer
Interventions
oxaliplatin, leucovorin calcium, fluorouracil, bevacizumab, yttrium Y 90 DOTA anti-CEA monoclonal antibody M5A, laboratory biomarker analysis, pharmacological study, irinotecan hydrochloride
Drug · Biological · Radiation + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jul 19, 2016 · Synced Oct 22, 2026, 1:35 AM EDT
Withdrawn Not applicable Interventional

Treat-and-resect Study of Echo Decorrelation Imaging-controlled Radiofrequency Ablation in Liver Tumors

NCT05211388
View directory record Official record
Conditions
Liver Tumor
Interventions
RFA controlled using echo decorrelation imaging, RFA controlled using standard manufacturer-specified algorithms
Procedure
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 29, 2024 · Synced Oct 22, 2026, 1:35 AM EDT
Withdrawn Phase 4 Interventional

Direct Peritoneal Resuscitation Plus Conventional Resuscitation

NCT01882218
View directory record Official record
Conditions
Hepatic Cancer
Interventions
Galactose, Standard Treatment
Drug
Lead sponsor
University of Louisville
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
2
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated May 5, 2017 · Synced Oct 22, 2026, 1:35 AM EDT
Completed Phase 3 Interventional Results available

A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation

NCT04102098
View directory record Official record
Conditions
Carcinoma, Hepatocellular
Interventions
Atezolizumab, Bevacizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
668 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
8
States / cities
Los Angeles, California • Baltimore, Maryland • Detroit, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2026 · Synced Oct 22, 2026, 1:35 AM EDT
Terminated No phase listed Observational

A 48 Subject Study Using Non-invasive Multi-Technology Measurements for Early Detection of Ongoing Hemorrhage

NCT04814810
View directory record Official record
Conditions
Occult Bleeding, Hemorrhage, Hemorrhagic Shock
Interventions
Not listed
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 5, 2022 · Synced Oct 22, 2026, 1:35 AM EDT
Terminated Not applicable Interventional Results available

Isoflurane Preconditioning for Liver Resections

NCT01031550
View directory record Official record
Conditions
Liver Disease
Interventions
isoflurane, propofol
Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 20, 2017 · Synced Oct 22, 2026, 1:35 AM EDT
Completed Not applicable Interventional

Comparison Between Epidural and Bilateral Paravertebral Blocks in Liver Resection

NCT01407666
View directory record Official record
Conditions
Liver Disease, Pain
Interventions
paravertebral blocks
Procedure
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 3, 2014 · Synced Oct 22, 2026, 1:35 AM EDT
Completed No phase listed Observational

Adult-to-Adult Living Donor Liver Transplantation Study

NCT00096733
View directory record Official record
Conditions
Cirrhosis, Hepatitis C, Hepatocellular Carcinoma
Interventions
Not listed
Lead sponsor
Arbor Research Collaborative for Health
Other
Eligibility
18 Years and older
Enrollment
2,470 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
9
States / cities
Los Angeles, California • San Francisco, California • Denver, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2017 · Synced Oct 22, 2026, 1:35 AM EDT
Recruiting Phase 1 Interventional

Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors

NCT07517198
View directory record Official record
Conditions
Solid Tumor, Small Cell Lung Cancer (SCLC), High Grade Neuroendocrine Cancer, Small Cell Carcinomas of Non-lung Origin, Non-small Cell Lung Cancer (NSCLC), Prostate Cancer, Ovarian Cancer, Renal Carcinoma (Clear and Non-clear Cell), Head and Neck Squamous Cell Carcinoma (HNSCC), Hepatic Cancer, Gastric Cancer, Triple-negative Breast Cancer (TNBC)
Interventions
EXS74539
Drug
Lead sponsor
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
3
States / cities
Los Angeles, California • Fort Worth, Texas • West Valley City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Oct 22, 2026, 1:35 AM EDT
Completed Phase 2 Interventional

Floxuridine, Dexamethasone, and Irinotecan After Surgery in Treating Patients With Liver Metastases From Colorectal Cancer

NCT00003753
View directory record Official record
Conditions
Colorectal Cancer, Metastatic Cancer
Interventions
dexamethasone, floxuridine, irinotecan hydrochloride, adjuvant therapy, conventional surgery
Drug · Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2004
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2013 · Synced Oct 22, 2026, 1:35 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Metabolomics of Liver Regeneration Following Partial Hepatectomy in Healthy Living Liver Donors

NCT01922323
View directory record Official record
Conditions
Liver Insufficiency
Interventions
Not listed
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 28, 2017 · Synced Oct 22, 2026, 1:35 AM EDT
Recruiting No phase listed Observational

DRAGON Registry - International Multicenter Registry and Medical Image Bank for Patients With Primarily Unresectable Liver Cancer or Liver Metastases That Underwent Combined Portal and Hepatic Vein Embolization (PVE/HVE) to Increase Future Liver Remnant Before Resection.

NCT07717437
View directory record Official record
Conditions
Liver Cancer, Liver Metastases
Interventions
Not listed
Lead sponsor
Maastricht University Medical Center
Other
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2032
U.S. locations
3
States / cities
Chicago, Illinois • Rochester, Minnesota • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Oct 22, 2026, 1:35 AM EDT
Completed Phase 3 Interventional

Controlled Trial Comparing Nomogram-based Versus Standard Allocation of Acute Normovolemic Hemodilution (ANH) During Hepatic Resection

NCT00902343
View directory record Official record
Conditions
Liver Cancer
Interventions
nomogram-based selection for acute normovolemic hemodilution, standard selection for ANH based on a planned resection of 3 or more segments
Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 13, 2015 · Synced Oct 22, 2026, 1:35 AM EDT
Completed No phase listed Observational

Does a Minimally Invasive Approach to Liver Resection Improve Postoperative Outcomes?

NCT07169877
View directory record Official record
Conditions
Hepatic Neoplasms
Interventions
Not listed
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
9,411 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 12, 2025 · Synced Oct 22, 2026, 1:35 AM EDT
Not listed Not applicable Interventional

Assessment of Augmented Reality in Minimally Invasive Surgery

NCT03678220
View directory record Official record
Conditions
Laparoscopic Hepatectomy, Laparoscopic Liver Thermal Ablation
Interventions
LapAR
Device
Lead sponsor
IGI Technologies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 26, 2019 · Synced Oct 22, 2026, 1:35 AM EDT
Completed Phase 2 Interventional Results available

Perioperative MVT-5873, a Fully Human Monoclonal Antibody Against a CA 19-9 Epitope, for Operable CA 19-9 Producing Pancreatic Cancers, Cholangiocarcinomas, and Metastatic Colorectal Cancers

NCT03801915
View directory record Official record
Conditions
Colon Cancer, Pancreatic Cancer, Cholangiocarcinoma, Metastatic Colon Carcinoma, Liver Metastasis
Interventions
MVT-5873, pancreatectomy or hepatectomy
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 21, 2023 · Synced Oct 22, 2026, 1:35 AM EDT
Recruiting No phase listed Observational

Evaluation of Resection Techniques for Pancreatic Tumors

NCT05128890
View directory record Official record
Conditions
Surgery, Liver Tumor, Pancreas Tumor
Interventions
Resection techniques for pancreatic and liver tumors
Procedure
Lead sponsor
Methodist Health System
Other
Eligibility
18 Years and older
Enrollment
431 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 20, 2026 · Synced Oct 22, 2026, 1:35 AM EDT
Active, not recruiting Phase 2 Interventional

Hepatic Arterial Infusion With Floxuridine and Dexamethasone Combined With Combination Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver

NCT00492999
View directory record Official record
Conditions
Colorectal Cancer, Metastatic Cancer
Interventions
dexamethasone, floxuridine, fluorouracil, irinotecan hydrochloride, leucovorin calcium, oxaliplatin
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2027
U.S. locations
5
States / cities
Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 22, 2026, 1:35 AM EDT